CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- NCT06470841
- Lead Sponsor
- Navy General Hospital, Beijing
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - The patient should, in the investigator's opinion, be able to meet all clinical<br> trial requirements.<br><br> - The patient is willing and able to adhere to the study visit schedule and other<br> protocol requirements.<br><br> - The patient should be diagnosed with AML according to the standard criteria of the<br> World Health Organisation (WHO).<br><br> - The patient should not have received any prior treatment for AML.<br><br>Exclusion Criteria:<br><br> - Active or uncontrolled infections requiring systemic treatment within 14 days before<br> enrollment.<br><br> - Any instability of systemic disease, including but not limited to severe cardiac,<br> liver, kidney, or metabolic disease need therapy.<br><br> - Pregnant or lactating women.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Response Rate (ORR)
- Secondary Outcome Measures
Name Time Method Overall Survival (OS);Progression Free Survival (PFS)